Literature DB >> 31250273

Klotho Is Neuroprotective in the Superoxide Dismutase (SOD1G93A) Mouse Model of ALS.

Ella Zeldich1,2, Ci-Di Chen1,2, Emma Boden1, Bryce Howat3, Jason S Nasse1, Dean Zeldich3, Anthony G Lambert3, Andrea Yuste2, Jonathan D Cherry4, Rebecca M Mathias4,5, Qicheng Ma1, Nelson C Lau1,6, Ann C McKee4,5,7, Theo Hatzipetros8, Carmela R Abraham9,10,11.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of motor neurons in the brain and spinal cord. ALS neuropathology is associated with increased oxidative stress, excitotoxicity, and inflammation. We and others reported that the anti-aging and cognition-enhancing protein Klotho is a neuroprotective, antioxidative, anti-inflammatory, and promyelinating protein. In mice, its absence leads to an extremely shortened life span and to multiple phenotypes resembling human aging, including motor and hippocampal neurodegeneration and cognitive impairment. In contrast, its overexpression extends life span, enhances cognition, and confers resistance against oxidative stress; it also reduces premature mortality and cognitive and behavioral abnormalities in an animal model for Alzheimer's disease (AD). These pleiotropic beneficial properties of Klotho suggest that Klotho could be a potent therapeutic target for preventing neurodegeneration in ALS. Klotho overexpression in the SOD1 mouse model of ALS resulted in delayed onset and progression of the disease and extended survival that was more prominent in females than in males. Klotho reduced the expression of neuroinflammatory markers and prevented neuronal loss with the more profound effect in the spinal cord than in the motor cortex. The effect of Klotho was accompanied by reduced expression of proinflammatory cytokines and enhanced the expression of antioxidative and promyelinating factors in the motor cortex and spinal cord of Klotho × SOD1 compared to SOD1 mice. Our study provides evidence that increased levels of Klotho alleviate ALS-associated pathology in the SOD1 mouse model and may serve as a basis for developing Klotho-based therapeutic strategies for ALS.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Microglia; Motor neurons; Neurodegeneration; Neuroinflammation; Therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31250273      PMCID: PMC7008951          DOI: 10.1007/s12031-019-01356-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  97 in total

Review 1.  Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis.

Authors:  P Needleman; P T Manning
Journal:  Osteoarthritis Cartilage       Date:  1999-07       Impact factor: 6.576

2.  Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey.

Authors:  J A Sloane; J D Hinman; M Lubonia; W Hollander; C R Abraham
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

3.  Activation of calpain-1 in myelin and microglia in the white matter of the aged rhesus monkey.

Authors:  Jason D Hinman; James A Duce; Robert A Siman; William Hollander; Carmela R Abraham
Journal:  J Neurochem       Date:  2004-04       Impact factor: 5.372

4.  Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress.

Authors:  Taku Nagai; Kiyofumi Yamada; Hyoung-Chun Kim; Yong-Sun Kim; Yukihiro Noda; Akihiro Imura; Yo-ichi Nabeshima; Toshitaka Nabeshima
Journal:  FASEB J       Date:  2002-11-15       Impact factor: 5.191

5.  Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis.

Authors:  G Almer; S Vukosavic; N Romero; S Przedborski
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

6.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Authors:  B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

7.  Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.

Authors:  Jenny S Henkel; Joseph I Engelhardt; László Siklós; Ericka P Simpson; Seung H Kim; Tianhong Pan; J Clay Goodman; Teepu Siddique; David R Beers; Stanley H Appel
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

8.  High-yield isolation of murine microglia by mild trypsinization.

Authors:  Josep Saura; Josep Maria Tusell; Joan Serratosa
Journal:  Glia       Date:  2003-12       Impact factor: 7.452

9.  VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death.

Authors:  Baolin Li; Wei Xu; Chun Luo; David Gozal; Rugao Liu
Journal:  Brain Res Mol Brain Res       Date:  2003-03-17

10.  Assessing disease onset and progression in the SOD1 mouse model of ALS.

Authors:  Patrick Weydt; So Yon Hong; Michel Kliot; Thomas Möller
Journal:  Neuroreport       Date:  2003-05-23       Impact factor: 1.837

View more
  7 in total

1.  A method to specifically activate the Klotho promoter by using zinc finger proteins constructed from modular building blocks and from naturally engineered Egr1 transcription factor backbone.

Authors:  Ci-Di Chen; Melissa A Rudy; Ella Zeldich; Carmela R Abraham
Journal:  FASEB J       Date:  2020-04-29       Impact factor: 5.191

2.  PTSD and the klotho longevity gene: Evaluation of longitudinal effects on inflammation via DNA methylation.

Authors:  Erika J Wolf; Mark W Logue; Xiang Zhao; Nikolaos P Daskalakis; Filomene G Morrison; Shaline Escarfulleri; Annjanette Stone; Steven A Schichman; Regina E McGlinchey; William P Milberg; Cidi Chen; Carmela R Abraham; Mark W Miller
Journal:  Psychoneuroendocrinology       Date:  2020-04-13       Impact factor: 4.905

3.  Serum Levels of α-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function.

Authors:  Payel Kundu; Benjamin Zimmerman; Joseph F Quinn; Jeffrey Kaye; Nora Mattek; Shawn K Westaway; Jacob Raber
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 4.  Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Iphigenia Kanara; Anastasios N Mavrakis; Julie Pernokas; Mark Pernokas; Carl A Pinkert; Whitney R Powers; Konstantina Sampani; Kosta Steliou; Demetrios G Vavvas; Robert J Zamboni; Krishna Kodukula; Xiaohong Chen
Journal:  Biores Open Access       Date:  2020-03-31

Review 5.  Little Helpers or Mean Rogue-Role of Microglia in Animal Models of Amyotrophic Lateral Sclerosis.

Authors:  Hilal Cihankaya; Carsten Theiss; Veronika Matschke
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

6.  Klotho, PTSD, and advanced epigenetic age in cortical tissue.

Authors:  Erika J Wolf; Ci-Di Chen; Xiang Zhao; Zhenwei Zhou; Filomene G Morrison; Nikolaos P Daskalakis; Annjanette Stone; Steven Schichman; Jaclyn Garza Grenier; Dana Fein-Schaffer; Bertrand R Huber; Carmela R Abraham; Mark W Miller; Mark W Logue
Journal:  Neuropsychopharmacology       Date:  2020-10-23       Impact factor: 7.853

Review 7.  A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.

Authors:  Georgios Pampalakis; Georgios Angelis; Eleni Zingkou; Kostas Vekrellis; Georgia Sotiropoulou
Journal:  Clin Transl Med       Date:  2022-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.